Sanofi Pasteur Korea appoint new General Manager

pharmafile | July 26, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Sanofi Pasteur, biotech, drugs, pharma, pharmaceutical 

Sanofi Pasteur Korea has announced that Baptiste de Clarens will be the new General Manager of the unit, after the previous incumbent, Regis Launay, moved onto become Global Franchise Head for Paediatric and Booster Vaccines.

de Clarens begins the role after having previously worked as Managing Director for Malaysia, Singapore and Brunei – a role he occupied for three and a half years. Prior to this, he worked in Singapore as Business Operations Director for Asia. Predominantly, he has been based in Asia, working in a variety of roles across Sanofi Pasteur, where his roles have been focused on sales.

He will have to draw on this experience to maintain Sanofi Pasteur’s major contribution to the domestic vaccine market in South Korea. The company supplies the market with the influenza vaccine, diphtheria, tetanus, pertussis vaccine, DTaP-IPV combo vaccine, Hib vaccine, meningococcal vaccine, Japanese encephalitis live vaccine and hepatitis A vaccine.

“It is a great honour and privilege for me to serve as GM of South Korea where Sanofi Pasteur has continued its commitment to the local market since 1989. I am looking forward to working together with Korean colleagues to empower Koreans to live life to the fullest,” Baptiste de Clarens said upon his appointment.

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content